Cannabigerol Relaxes Human Pulmonary Arteries Through Multiple Pathways
An ex vivo study found cannabigerol (CBG) relaxes human pulmonary arteries through endothelium-dependent mechanisms involving nitric oxide, cyclooxygenase, and potassium channels, modified by hypertension and high cholesterol.
Quick Facts
What This Study Found
CBG relaxed human pulmonary arteries through endothelium-dependent mechanisms involving cyclooxygenase, nitric oxide, K+ channels, and likely CB1/CB2, PPARgamma, GPR55, and TRPV1 receptors. Hypertension and hypercholesterolaemia modified the response.
Key Numbers
At least 4 mechanistic pathways; response modified by hypertension and hypercholesterolaemia; endothelium removal abolished the effect.
How They Did This
Ex vivo study using human pulmonary artery segments. Vascular reactivity measured with selective pathway inhibitors. Post-hoc comorbidity analysis.
Why This Research Matters
First study showing CBG can relax human pulmonary arteries, with specific mechanisms identified and clinical comorbidity effects documented.
The Bigger Picture
CBG combined with anti-inflammatory and antioxidant properties could be relevant for cardiovascular applications, though mild potency tempers expectations.
What This Study Doesn't Tell Us
Ex vivo tissue. Post-hoc comorbidity analysis. CBG concentrations may not be achievable orally. Surgical patients may not represent general population.
Questions This Raises
- ?Could CBG benefit pulmonary hypertension patients?
- ?How does CBG compare to CBD in pulmonary arteries?
Trust & Context
- Key Stat:
- CBG vasorelaxation required intact endothelium
- Evidence Grade:
- First human tissue demonstration with pathway analysis, but ex vivo design limits translation.
- Study Age:
- 2025 study providing first CBG data in human pulmonary vasculature.
- Original Title:
- Ex vivo study of the vasorelaxant activity induced by cannabigerol in human pulmonary artery- the role of endothelium, sex and selected clinical factors.
- Published In:
- Biochemical pharmacology, 242(Pt 1), 117383 (2025)
- Authors:
- Krzyżewska, Anna(2), Kloza, Monika, Kozłowski, Mirosław, Galicka, Anna, Kozłowska, Hanna
- Database ID:
- RTHC-06867
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What is CBG?
A non-psychoactive cannabinoid with anti-inflammatory properties. This study adds vasorelaxant effects in human pulmonary arteries.
Could CBG help with pulmonary hypertension?
It relaxes pulmonary arteries ex vivo through multiple mechanisms, but clinical translation requires further research.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06867APA
Krzyżewska, Anna; Kloza, Monika; Kozłowski, Mirosław; Galicka, Anna; Kozłowska, Hanna. (2025). Ex vivo study of the vasorelaxant activity induced by cannabigerol in human pulmonary artery- the role of endothelium, sex and selected clinical factors.. Biochemical pharmacology, 242(Pt 1), 117383. https://doi.org/10.1016/j.bcp.2025.117383
MLA
Krzyżewska, Anna, et al. "Ex vivo study of the vasorelaxant activity induced by cannabigerol in human pulmonary artery- the role of endothelium, sex and selected clinical factors.." Biochemical pharmacology, 2025. https://doi.org/10.1016/j.bcp.2025.117383
RethinkTHC
RethinkTHC Research Database. "Ex vivo study of the vasorelaxant activity induced by cannab..." RTHC-06867. Retrieved from https://rethinkthc.com/research/krzyzewska-2025-ex-vivo-study-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.